Immuneering (IMRX) director Thomas Schall boosts stake with 21,645-share buy

Rhea-AI Filing Summary

Immuneering Corp director Thomas J. Schall reported buying additional Class A common stock. On January 15, 2026, he purchased 21,645 shares of Immuneering Class A common stock in an open-market transaction coded as a purchase. The weighted average price was $4.6681 per share, with individual trades executed through a broker-dealer at prices ranging from $4.61 to $4.69. Following this transaction, Schall directly beneficially owns 74,530 shares of Immuneering Class A common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schall Thomas J.

(Last) (First) (Middle)

C/O IMMUNEERING CORPORATION

245 MAIN STREET, 2ND FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	01/15/2026		P		21,645	A	$4.6681(1)	74,530	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.61 to $4.69. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Thomas J. Schall	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Immuneering Corp (IMRX) report for Thomas J. Schall?

Immuneering Corp reported that director Thomas J. Schall purchased 21,645 shares of its Class A common stock in an open-market transaction on January 15, 2026.

At what price did Thomas J. Schall buy Immuneering (IMRX) shares?

The reported weighted average purchase price was $4.6681 per share, with trades executed through a broker-dealer at prices between $4.61 and $4.69 per share.

How many Immuneering (IMRX) shares does Thomas J. Schall own after this transaction?

After the reported purchase, Thomas J. Schall directly beneficially owns 74,530 shares of Immuneering Corp Class A common stock.

What is the role of Thomas J. Schall at Immuneering Corp (IMRX)?

Thomas J. Schall is listed as a director of Immuneering Corp and is not reported as an officer or 10% owner in this filing.

Was the Immuneering (IMRX) insider transaction a purchase or a sale?

The Form 4 reports a purchase transaction, coded "P", indicating that Thomas J. Schall acquired additional Immuneering Class A common shares.

How were the Immuneering (IMRX) shares acquired by Thomas J. Schall executed?

The filing states that the transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.61 to $4.69 per share.